Early Data Links Wegovy to Risk of 'Eye Stroke' — Here's What to Know

Why It Matters

If confirmed, an ION risk could reshape prescribing practices for popular obesity treatments and trigger regulatory scrutiny, affecting both patient safety and market dynamics.

Key Takeaways

• Study found 28 ION cases among 3,070 Wegovy reports.
• Proportional ION risk higher for Wegovy than Ozempic.
• Reports are unverified; signal needs further clinical investigation.
• Higher semaglutide dose may raise ION risk, but evidence is limited.
• Regulators advise urgent care for sudden vision loss on semaglutide.

Pulse Analysis

Wegovy’s rapid adoption for chronic weight management has been buoyed by its recent pill formulation, but the drug’s safety profile is now under fresh scrutiny. A March 2026 study in the British Journal of Ophthalmology mined FDA adverse‑event submissions from 2017‑2024, uncovering 28 instances of ischemic optic neuropathy (ION) linked to Wegovy out of 3,070 reports. While the absolute incidence remains well under 1%, the proportional risk appears higher than that observed for Ozempic, its diabetes‑focused counterpart, prompting clinicians to monitor visual symptoms more closely.

The analysis, however, is limited by its reliance on self‑reported, unverified data. Experts note that such pharmacovigilance databases are valuable for flagging potential safety signals but cannot establish prevalence or causality. Confounding factors—such as the higher baseline cardiovascular risk among semaglutide users, the drug’s dosage differences, and overlapping diabetes comorbidities—complicate the interpretation. Moreover, the newer semaglutide pill, Rybelsus, showed no notable ION association, suggesting that formulation and patient population may influence outcomes.

Regulatory bodies are responding cautiously. The UK’s Medicines and Healthcare products Regulatory Agency now urges anyone on semaglutide who experiences sudden vision loss to seek immediate medical attention. For prescribers, the emerging signal underscores the need for thorough ocular assessments and patient education about warning signs. As further epidemiological studies and prospective trials unfold, the industry may see adjustments in labeling, dosing recommendations, or post‑marketing surveillance protocols, all of which could impact Wegovy’s market trajectory and investor confidence.